Study on the antiplatelet therapeutic effect of indobufen in patients with hemodialysis and acute coronary syndrome after percutaneous coronary intervention
Objective:To evaluate the antiplatelet therapeutic effect and safety of indobufen in patients with acute coronary syndrome(ACS)undergoing percutaneous coronary intervention(PCI)who are also on hemodialysis.Methods:A total of 80 patients who underwent PCI post-ACS with concurrent hemodialysis at our hospital from May 2021 to May 2023 were selected as the subjects of this study.They were randomly divided into an indobufen group and a control group.The indobufen group was treated with indobufen(100 mg,twice per day)plus clopidogrel(75 mg,once per day),while the control group was treated with aspirin(100 mg,once per day)plus clopidogrel(75 mg,once per day).The study compared the platelet count,platelet aggregation rate(PAR)via the arachidonic acid(AA)pathway,and adenosine diphosphate(ADP)pathway PAR before and 48 hours after medication.Follow-up visits were conducted at 1 month and 6 months to record and compare the incidence of new myocardial infarction,cardiac death,stroke,and other major adverse cardiovascular events(MACE),as well as bleeding and gastrointestinal adverse reactions between the two groups.Results:Both groups showed a significant decrease in PARAA and PARADP after medication compared to before medication(P＜0.05),but there was no statistical difference between the groups before and after medication(all P＞0.05).At the 6-month follow-up,the incidence of bleeding events and gastrointestinal adverse reactions in the indobufen group was found to be lower than in the control group,with a statistically significant difference(P＜0.05).Conclusion:In patients with hemodialysis and acute coronary syndrome undergoing PCI,indobufen can effectively reduce platelet aggregation rates,with therapeutic effects comparable to those of aspirin,and has a lower incidence of bleeding and gastrointestinal adverse reactions,indicating better safety.
NETL
NSTL
万方数据
